Provided by Tiger Fintech (Singapore) Pte. Ltd.

Relay Therapeutics

3.66
+0.25007.33%
Post-market: 3.59-0.0700-1.91%19:56 EDT
Volume:2.13M
Turnover:7.56M
Market Cap:620.45M
PE:-1.55
High:3.66
Open:3.40
Low:3.35
Close:3.41
Loading ...

Relay Therapeutics Inc expected to post a loss of 56 cents a share - Earnings Preview

Reuters
·
25 Feb

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

GlobeNewswire
·
25 Feb

Positive Outlook for Relay Therapeutics: Buy Rating on Promising RLY-2680 Developments and Market Opportunities

TIPRANKS
·
29 Jan

Relay Therapeutics Inc (RLAY): AI-Driven Cancer Treatments Backed by Barclays’ $17 Price Target

Insider Monkey
·
25 Jan

We're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate

Simply Wall St.
·
17 Jan

Relay Therapeutics (RLAY) Gets a Buy from Barclays

TIPRANKS
·
17 Jan

Relay Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Jan

Relay Therapeutics: Positioned for Success with Best-in-Class PI3Kα Inhibitor RLY-2608

TIPRANKS
·
14 Jan

Is Relay Therapeutics (RLAY) the Best Biotech Penny Stock to Invest in Now?

Insider Monkey
·
31 Dec 2024

Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade

Zacks
·
21 Dec 2024

Relay Therapeutics, Inc. (RLAY): A Bull Case Theory

Insider Monkey
·
14 Dec 2024

TD Cowen Reaffirms Their Buy Rating on Relay Therapeutics (RLAY)

TIPRANKS
·
12 Dec 2024

Relay Therapeutics (RLAY) Gets a Buy from Barclays

TIPRANKS
·
12 Dec 2024

Relay Therapeutics’ RLY-2608: Promising Data and Strategic Plans Reinforce Buy Rating

TIPRANKS
·
12 Dec 2024

Relay Therapeutics Shares up 9.4% After Co Reports Interim Data for Breast Cancer Drug

THOMSON REUTERS
·
11 Dec 2024

Relay Therapeutics Says RLY-2608 With Fulvestrant Data Shows 'Clinically Meaninful' Metastatic Breast Cancer Survival

MT Newswires Live
·
11 Dec 2024